Healthcare systems worldwide are facing a new weight-loss treatment in the form of injections containing semaglutide, marketed as Wegovy or Ozempic.
The United Kingdom is one of the first countries to potentially offer semaglutide as a publicly funded weight-loss treatment. However, there is concern among many doctors that England’s guidance body has made a mistake by recommending a maximum duration of two years for its use, despite the drug’s intended long-term usage. This has prompted health systems in other countries to also consider how to address this unprecedented issue.
